We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Intercytex | LSE:ICX | London | Ordinary Share | GB00B0762609 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 4.125 | 0.00 | 01:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 4.125 | GBX |
Intercytex (ICX) Share Charts1 Year Intercytex Chart |
|
1 Month Intercytex Chart |
Intraday Intercytex Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 21/12/2012 | 10:42 | Intercytex - Miracles can happen | 2,584 |
| 08/5/2009 | 08:50 | INTERCYTEX (baldness cure) - AIM listed 01.Feb.06 @ 108p | 311 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 19/4/2011 18:16 by the_doctor 'Why the heck should we'well hyper, since it's you that wants to find out more 'So why did the company restrain from releasing that news?' perhaps because given the writing was on the wall, people like you would have argued afterwards that you were misled by them releasing positive news. 'Why did the company not use that positive development for fund raising?' because there was no longer a business! 'Yes we all know it's high risk, but if you can't asses the risk because shareholders are kept in the dark' you werent kept in the dark. Everything rested on a Phase III study. That failed and these were the consequences - sorry 'why did the company then sell their most valuable asset to Pfizer for just £750k and us share holders received NONE of it' creditors Like I said Hyper. If YOU want full answers to these questions, ask the people involved directly IMO. |
Posted at 19/4/2011 18:11 by hyper al the_doctorWhy the heck should we have to contact these people for info that they should have made available to shareholders. Yes anyone can phone the directors or whoever, but it is they, that should have informed their shareholders of what was happening prior to suspension. They did not. The fact that Pfizer announced support for the London project, should have been a big positive for the company, they only announced that in an RNS after being pushed by shareholders when the news was reported in the press and sent the share price rocketing and continued up after the RNS. So why did the company restrain from releasing that news? Why did the company not use that positive development for fund raising? and then the big question, why did the company then sell their most valuable asset to Pfizer for just £750k and us share holders received NONE of it! I have taken the loss, it's not a problem, but this company has done more damage to UK investment in Stem Cell research than any other UK company in this field. I see absolutely no benefits for UK investors in this sector. Yes we all know it's high risk, but if you can't asses the risk because shareholders are kept in the dark, then it is just money down the drain! My last word on this matter. Goodbye £7.5k or whatever it was, it's now gone from my screen! |
Posted at 23/3/2011 22:03 by whibbled Following my emails to the Joint Liquidators (and whilst writing 2564 above)the following copy of a letter to shareholders was forwarded to me by Max Herrmann.......LETTER FROM THE DIRECTORS OF REGENERATIVE MEDICINE ASSETS LIMITED (Incorporated and registered in England and Wales with registered number 5340010) Directors: Ian Kent, Non-Executive Chairman John Aston, Non-Executive Director Nick Higgins, Non-Executive Director Max Herrmann, Non-Executive Director Registered Office: C/O PKF UK LLP Farringdon Place 20 Farringdon Road London EC1M 3AP 14 March 2011 Dear Shareholder Introduction Regenerative Medicine Assets Limited (formerly Intercytex Group Plc) has now completed the sale of all assets detailed in its circular to shareholders dated 7 December 2009 ('the Circular'). The Directors appreciate that this has been a protracted process and wish to thank shareholders for their patience. Disappointingly, consideration received for the sale of the Company's assets was low. In particular, proceeds from the sale of ICX-TRC to Bosley were significantly below the initial indicative offer. In addition, a major milestone related to the transfer of the Company's Armed Forces Institute of Regenerative Medicine (AFIRM) grant to DFB Healthpoint was not achieved by 30th January 2011, the date after which payment of the milestone no longer became due. Waiting for this milestone has been the major issue in delaying the liquidation of the Company. As a result of the above factors, the Company has been left with insufficient cash to settle all outstanding creditors. However, in order to achieve a solvent liquidation of the Company, certain creditors have agreed to reduce their claims. The Directors will therefore swear a declaration as to the Company's solvency and now recommend to shareholders in the Company to place the Company into Members' Voluntary Liquidation ("MVL"). Whilst the MVL will not result in a distribution to shareholders, it will enable the Company to be liquidated in an orderly process and allow shareholders to recognize their losses. Members' Voluntary Liquidation MVL is a voluntary winding up procedure that can be adopted by the Directors where they are able to swear a declaration as to the Company's solvency and subsequently receive the required approval of Shareholders by way of Special Resolution. In an MVL it is anticipated that all of a Company's creditors will be paid in full. An MVL should not be confused with an insolvent liquidation, which takes place where a company is unable to pay its debts and is insolvent. The Directors have confirmed that the Company has sufficient cash resources to pay all its creditors. The Board proposes to appoint David Merrygold and Stephen Holgate of PKF (UK) LLP, 20 Farringdon Road, London EC1M 3AP as joint liquidators (the "Joint Liquidators") of the Company. Please note that share transfers following the commencement of the MVL are prohibited, save with the express consent of the joint liquidators. In the event that the Resolution for the MVL is not passed by the necessary majority at the General Meeting ('GM'), the directors will have no option but to commence proceedings to place the Company into either Compulsory Liquidation or Creditors Voluntary Liquidation, insolvent procedures. General Meeting The notice convening the GM to be held at the offices of PKF (UK) LLP, Farringdon Place, 20 Farringdon Road, London, EC1M 3AP at 12.00 a.m. on 30 March 2011 is set out at the end of this document. The purpose of GM is to authorise the following resolutions, by way of Special and Ordinary Resolutions: the voluntary winding up of the Company and appointment of David Merrygold and Stephen Holgate of PKF (UK) LLP as joint liquidators (the "Joint Liquidators") of the Company for the purposes of the MVL and to authorise them to act jointly and severally ; the Joint Liquidators be authorised to exercise such powers as may be necessary for the purposes of the liquidation under the provisions of the Insolvency Act; and to determine the basis of the Joint Liquidators'remunera Action to be taken A Form of Proxy for use at the GM is enclosed. If you are a Shareholder you are advised to complete and return the form in accordance with the instructions printed on it so as to arrive at the Company's registrars, Capita Registrars, Proxies Department, PO Box 25, Beckenham, Kent BR3 4BR, UK as soon as possible, but in any event no later than 12.00 a.m. on 28 March 2011. The return of a Form of Proxy does not preclude you from attending and voting at the GM if you so wish. Recommendations The Board believes the MVL to be in the best interests of the Company and its Shareholders as a whole. Accordingly, the Board unanimously recommends that the Shareholders vote in favour of the Resolutions at the GM as they will be doing with all their own shares. Yours faithfully Ian Kent Chairman Contact email: mherrmann@regenerati |
Posted at 18/3/2011 06:26 by the_doctor tonyknaggsI once went to the trouble of posting about new owners involved in the new company. Nobody bothered to call them up ICX went bust Some of the management will naturally have been kept on That doesnt mean they didnt accept the best price at the time? Call Max Hermann at SLN |
Posted at 18/3/2011 00:43 by hyper al How can any of this be allowed?How can the company continue operating after dumping all it's share holders and after supposedly selling almost all the company assets for the benefit of shareholders but without compensation to the shareholders? I've had enough of this behaviour. |
Posted at 17/3/2011 22:08 by whibbled Just to cheer all of us up...........Intercytex starts Phase II Clinical Trial Wednesday, March 16 2011 Intercytex Ltd is very pleased to be able to make the following press release following the Company's relaunch in November KING'S COLLEGE LONDON, INTERCYTEX AND DEBRA BEGIN PHASE II TRIAL WITH ICX-RHY IN PATIENTS WITH SEVERE GENETIC SKIN DISORDER, RDEB AT GUY'S HOSPITAL, LONDON London, Manchester and Crowthorne, UK, 15 March 2011..... King's College London; the regenerative medicine company Intercytex; and the patient charity DEBRA, announce the start of a Phase II trial with the Intercytex therapy ICX-RHY to treat skin erosions in patients suffering from the severe genetic skin disorderRecessive Dystrophic Epidermolysis Bullosa (RDEB). In such patients the skin blisters at the slightest knock or rub, causing painful, open wounds which result in scarring and fusion of fingers. The placebo controlled trial will involve 20 RDEB patients. It will be led by Professor John McGrath, Professor of Molecular Dermatology at King's College London and Honorary Consultant Dermatologist at Guy's and St Thomas' NHS Foundation Trust, London, who will administer a single series of ICX-RHYinjections or placebo around the margins of several selected skin erosions. The injections will take place at the Clinical Research Facilities at Guy's Hospital. Patients will then be assessed initially over a three month period to measure end points including time to wound closure, wound recurrence and erosion pain. The trial, which is scheduled for completion early in the autumn,is funded jointly by Intercytex, The Technology Strategy Board and DEBRA. Professor McGrath has already used ICX-RHY successfully to treat 14 EB patients on a compassionate use basis. Commenting on the start of the trial, Prof McGrath said 'Finding out whether a new treatment can help people with EB heal their wounds faster makes this an important clinical trial. We plan to test cells called "fibroblasts" to see if injection into the skin affects wound healing. The trial represents a significant step forward in taking research from the laboratory to the clinic.' Melissa Smith was born with RDEB and has lived with the condition for over 24 years. Melissa took part in preliminary studies with the therapy and is now preparing to participate in the Phase ll trial. Commenting on her involvement, Melissa said 'I am firmly committed to helping with these trials. When you have EB you live in constant pain. There is, of course, additional pain from the trial treatment but its short term and the therapy could offer such hope long term for me and others who live with EB.' Ben Merrett, CEO of DEBRA, added: 'Some forms of EB, like RDEB, can be very debilitating and there is a high unmet medical need for an effective treatment. Judging by the initial patient reaction to ICX-RHY,this could be an exciting step forward in treating the disease and make a significant, long-term difference to people who lead very difficult lives.' 'I am delighted that ICX-RHY has shown such early promise in a small number of RDEB patients' commented Dr Kemp, Intercytex's Chief Executive Officer. 'ICX-RHY is designated an Orphan Product in the EU and this trial marks a very significant step towards obtaining Regulatory Approval for the treatment. In the meantime we are actively looking at ways we can make this material available to other patients who are not able to be part of this trial. In addition to EB patients, ICX-RHY has also shown to have the potential to help heal burn and trauma scars and we are also trialling it in these indications.' One in 227 people have a defective gene that causes EB and the disease affects around 1 in 17,000 live births. It is estimated that there are half a million sufferers world wide and 5,000 people with EB in the UK. RDEB is one of the more severe, debilitating forms of the disease, with a prevalence of around 2 in 100,000. ICX-RHYis a suspension of human dermal fibroblasts (HDFs, which are naturally derived skin cells) in cell storage medium, for injection into the skin. The newly introduced HDFs are thought to repair the extracellular matrixto improve skin structure and function. ICX-RHYis designated as one of the first Advanced Therapy Medicinal Products (ATMP) by the European Medical Agency and has already been used in clinical trials and compassionate use programmes in over 100 patients in a variety of indications. |
Posted at 15/3/2011 21:00 by the_doctor any of you bothered to speak to the company out of interest?still not clear to me why some criticise the company - ICX went bust because the Phase III trial failed. That wasnt their fault |
Posted at 04/12/2010 15:32 by the_doctor 'ICX decided for it's own (directors) reasons not to continue'and the fact they didnt have enough money to do anything further 'Rubbish, I was in ICX for it's AMD research and the London Project' you invest in a company. if that company's future rests heavily on a product, then so does your investment 'When a mineral exploration company fails to get a JORC resource, it still has a business' some might do. Others not Reality is I'm afraid that after the failure, ICX no longer had a viable business in the shape/form it was in 'Why do the markets bother funding anything?' because they hope for a return. I dont think there was enough left in ICX to attract investors. It's possible that they covered up the value to take it for themselves, but I dont think that's clear. I posted on here various details about who was investing in the assets via a new business, but few seemed interested. Did you ever call them up to discuss etc? |
Posted at 04/12/2010 15:23 by hyper al 'the market still sees no value in stem cells'should it?? Well why should the market see any value in any untested drug or medical solution? Why do the markets bother funding anything? "but it was. and any investor could see that" Rubbish, I was in ICX for it's AMD research and the London Project. I think they could have got funding for that line of research, but decided they could not be bothered and went for the easy option. For mineral resources you have the JORC code, for drugs you have Phase I, II and III. If an explorer can't get a JORC resource it gives up and moves on to another project. ICX failed and should have moved on to it's AMD stem cell line, but instead it dumped everything. When a mineral exploration company fails to get a JORC resource, it still has a business, it finds the money via a placing and continues, OK share price takes a hammering, but it continues! Many AIM Pharmas still keep going after a Phase I, II or III failure; ICX decided for it's own (directors) reasons not to continue. ICX lab was almost unique in the UK and had lots of money spent on it! It even appears that ABH may have taken over their old labs, although I don't have any direct evidence of that yet. |
Posted at 04/12/2010 14:26 by hyper al the_doctorSorry my experience suggests that AIM resource stocks are far safer than AIM biotech/pharma If a metals explorer does not locate an economic resource they don't suspend the share and go into receivership, they get more funds and move onto the next exploration target. They tend to have 3 or more exploration targets so they always have something to fall back on. ICX had a few projects, but the markets don't treat biotech/pharma listed companies the same as mineral explorers and it appears ICX could not find the funds or did not try. ICX should not have got into the position where it was hugely reliant upon the success of a single trial. ICX's research and patent on the AMD cell line handed over to Pfizer or just £750k sums this sector up as an investment. You don't see a 10 million oz gold field getting sold for £750k and that is about it, the market still sees no value in stem cells! I wish the markets did treat these companies the same as mineral explorers, it would at least give them a chance. If RENE's current trial fails, will that be the end of RENE, the way the markets treat these companies, I think it will, but it would be a total disgrace! |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
